Author/Authors :
Meyer، نويسنده , , Lüder Hinrich and Eckhoff، نويسنده , , Sarah Mirjam and Queudeville، نويسنده , , Manon and Kraus، نويسنده , , Johann Michael and Giordan، نويسنده , , Marco and Stursberg، نويسنده , , Jana and Zangrando، نويسنده , , Andrea and Vendramini، نويسنده , , Elena and Mِricke، نويسنده , , Anja K. Zimmermann، نويسنده , , Martin and Schrauder، نويسنده , , Andre and Lahr، نويسنده , , Georgia and Holzmann، نويسنده , , Karlheinz and Schrappe، نويسنده , , Martin and Basso، نويسنده , , Giuseppe and Stahnke، نويسنده , , Karsten and Kestler، نويسنده , , Hans Armin and te Kronnie، نويسنده , , Geertruy and Debatin، نويسنده , , Klaus-Michael، نويسنده ,
Abstract :
Summary
estigated the engraftment properties and impact on patient outcome of 50 pediatric acute lymphoblastic leukemia (ALL) samples transplanted into NOD/SCID mice. Time to leukemia (TTL) was determined for each patient sample engrafted as weeks from transplant to overt leukemia. Short TTL was strongly associated with high risk for early relapse, identifying an independent prognostic factor. This high-risk phenotype is reflected by a gene signature that upon validation in an independent patient cohort (n = 197) identified a high-risk cluster of patients with early relapse. Furthermore, the signature points to independent pathways, including mTOR, involved in cell growth and apoptosis. The pathways identified can directly be targeted, thereby offering additional treatment approaches for these high-risk patients.
